

# The interrelationships between changes in the metabolic state and homeostasis of the bone and injection of a new substance during orthodontic tooth movement

<b>Submission date</b> 28/04/2024	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 07/05/2024	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 07/05/2024	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Tooth anchorage control is one of the main factors determining the success of orthodontic treatment. The challenge is to design a system that maximizes desirable tooth movements and also minimizes anchorage loss, especially in adult patients demanding a more convenient treatment with orthodontic appliances to control unfavourable tooth movement. Bisphosphonate drugs may reduce orthodontic tooth movement due to their effects on bone turnover. Therefore, the aim of this study is to assess the use of the bisphosphonate drug zoledronic acid to prevent anchorage loss in orthodontic treatment.

### Who can participate?

Patients aged 18-25 years old with skeletal class II malocclusion (overbite)

### What does the study involve?

Patients will be randomly allocated into two groups to be treated with either zoledronic acid or placebo injection only once before starting the mass retraction, and are followed up until the retraction period ends (6-8 months).

### What are the possible benefits and risks of participating?

Bisphosphonates can strengthen tooth anchorage during orthodontic treatment. Bisphosphonates may have side effects at high concentrations, which are not used in this study.

### Where is the study run from?

Damascus University (Syria)

### When is the study starting and how long is it expected to run for?

April 2022 to June 2024

Who is funding the study?  
Damascus University (Syria)

Who is the main contact?  
Dr Fryal Rahme, fryalrahme3@gmail.com

## Contact information

### Type(s)

Public, Scientific

### Contact name

Dr Fryal Rahme

### Contact details

Department of Orthodontics  
Faculty of Dentistry  
Damascus University  
Al-Mazzeah St  
Damascus  
Syria  
0004  
+963 (0)99492798  
fryal3.rahme@damascusuniversity.edu.sy

### Type(s)

Scientific, Principal investigator

### Contact name

Dr Ahmad Burhan

### ORCID ID

<https://orcid.org/0000-0002-0727-2653>

### Contact details

Department of Orthodontics  
Faculty of Dentistry  
Damascus University  
Al-Mazzeah St  
Damascus  
Syria  
0004  
+963 (0)944302075  
prof.ahmadburhan@damascusuniversity.edu.sy

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

**ClinicalTrials.gov (NCT)**

Nil known

**Protocol serial number**

4244

## Study information

### Scientific Title

Evaluation of the efficacy of locally injected zoledronic acid in increasing the anchorage during en-masse retraction of the maxillary anterior teeth: a randomized controlled clinical trial

### Study objectives

There are a significant differences between the experimental group and the control group in increasing the anchorage during mass retraction of the upper anterior teeth.

### Ethics approval required

Ethics approval required

### Ethics approval(s)

approved 29/08/2022, Scientific research and postgraduate studies council of Damascus (Damascus, Damascus, 0004, Syria; +963 (0)993303359; ap.srd@damascusuniversity.edu.sy), ref: 4244

### Study design

Interventional single-center single-blinded randomized parallel-group controlled trial

### Primary study design

Interventional

### Study type(s)

Efficacy

### Health condition(s) or problem(s) studied

Skeletal class II and moderate maxillary protrusion

### Interventions

Patients will be randomly allocated into two groups using Microsoft® Excel electronic randomization:

Group 1: Experimental group: the dental arch will first be aligned with wires 0.12, 0.14, 0.16, 16.22, 17.25, 19.25 NITI. Then the upper first premolars will be extracted and then will be applied the zoledronic acid to the patient through local injection mesial to the upper first molar on both the right and left sides and on the vestibular and palatal sides and then mass retraction of the upper anterior teeth will be started.

Group 2: The treatment protocol used in this group is the same as described in the experimental group, but placebo will be applied to the patient instead of zoledronic acid.

The medicinal substance is applied only once during the treatment before starting the mass retraction, and participants are followed up until the retraction period ends (6-8 months).

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Zoledronic acid

**Primary outcome(s)**

1. The amount of slippage of the upper first molars mesially during retraction
2. The inclination of the axes of the upper first molars
3. Rotation of maxillary first molars
4. The height of the alveolar bone in the injection area
5. The thickness of the alveolar bone in the injection area
6. Root resorption of maxillary first molars

Measured using cone beam computed tomography (CBCT) before the start of orthodontic treatment and after the end of the mass retraction

**Key secondary outcome(s)**

Pain and discomfort following injection measured using the visual analogue score (VAS) at baseline, 1, 3, and 7 days

**Completion date**

20/06/2024

**Eligibility****Key inclusion criteria**

1. Patient who has a second class II as light to medium with  $4 < ANB < 8$
2. In the vertical plane, a natural or slight vertical growth pattern
3. Moderate anchorage, where the molar and canine relationships are cusp to cusp
4. The mandibular dental arch is well aligned or slightly crowded and does not require extraction treatment
5. A patient with good oral health and healthy periodontal tissue
6. A patient who does not take any medications
7. A patient who has not undergone previous orthodontic treatment

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

25 years

**Sex**

All

**Key exclusion criteria**

1. Patients who have a severe structural defect in the sagittal plane
2. Patients who have a severe horizontal or vertical growth pattern
3. The patient who has moderate to severe crowding in the lower dental arch requires extraction to treat it
4. Patients with general diseases or craniofacial syndromes
5. Pregnant or breastfeeding

**Date of first enrolment**

01/04/2023

**Date of final enrolment**

01/12/2023

**Locations****Countries of recruitment**

Syria

**Study participating centre****Damascus University**

Department of Orthodontics

Faculty of Dentistry

Al-Mazzeah St

Damascus

Syria

80789

**Sponsor information****Organisation**

Damascus University

**ROR**

<https://ror.org/03m098d13>

**Funder(s)**

**Funder type**

University/education

**Funder Name**

Damascus University

**Alternative Name(s)**

University of Damascus, , DU

**Funding Body Type**

Government organisation

**Funding Body Subtype**

Universities (academic only)

**Location**

Syria

## Results and Publications

**Individual participant data (IPD) sharing plan**

The datasets generated and analyzed during the current study during this study will be included in the subsequent results publication.

**IPD sharing plan summary**

Published as a supplement to the results publication